Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 5 (5) , 411-415
- https://doi.org/10.1016/s1535-6108(04)00122-9
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2Journal of Clinical Oncology, 2004
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on PrognosisJournal of Clinical Oncology, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Autoinhibition ControlScience, 2003
- Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United StatesLung Cancer, 1996
- Epidermal growth factorBioscience Reports, 1986
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequencesNature, 1984